Oryzon Genomics Balance Sheet Health
Financial Health criteria checks 5/6
Oryzon Genomics has a total shareholder equity of $138.5M and total debt of $20.8M, which brings its debt-to-equity ratio to 15%. Its total assets and total liabilities are $169.8M and $31.3M respectively.
Key information
15.04%
Debt to equity ratio
US$20.82m
Debt
| Interest coverage ratio | n/a |
| Cash | US$33.33m |
| Equity | US$138.45m |
| Total liabilities | US$31.34m |
| Total assets | US$169.79m |
Recent financial health updates
Is Oryzon Genomics (BME:ORY) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Is Oryzon Genomics (BME:ORY) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Oryzon Genomics (BME:ORY) Has Debt But No Earnings; Should You Worry?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Recent updates
Financial Position Analysis
Short Term Liabilities: ORY's short term assets ($36.0M) exceed its short term liabilities ($18.5M).
Long Term Liabilities: ORY's short term assets ($36.0M) exceed its long term liabilities ($12.8M).
Debt to Equity History and Analysis
Debt Level: ORY has more cash than its total debt.
Reducing Debt: ORY's debt to equity ratio has reduced from 17.8% to 15% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ORY has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ORY has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/12 12:37 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Oryzon Genomics S.A. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jyoti Prakash | Edison Investment Research |
| Joaquin Garcia-Quiros | JB Capital Markets |
| Lucy Codrington | Jefferies LLC |